Sangamo BioSciences | SGMO - Interest Income


Sangamo BioSciences reported $2.8M in Interest Income for its fiscal quarter ending in June of 2023.





Interest Income Change Date
Alnylam Pharmaceuticals USD 27.49M 1.19M Jun/2025
Bayer EUR 130M 38M Sep/2025
BioCryst Pharmaceuticals USD -0.13 3.59M Dec/2024
Biogen USD 31.6M 700K Sep/2025
BioMarin Pharmaceutical USD 18.83M 186K Jun/2025
Compugen USD 954K 116K Sep/2025
CSL USD 18M 1000K Dec/2024
Gilead Sciences USD 88M 15M Sep/2025
GlaxoSmithKline GBP 26M 24M Sep/2025
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
J&J USD 2.12 0.17 Sep/2025
Karyopharm Therapeutics USD -0.15 0.11 Dec/2024
Merck USD 96M 27M Sep/2025
Pfizer USD 0.62 156M Sep/2025
Sanofi EUR 114M 38M Sep/2025
Sarepta Therapeutics USD 7.14M 3.05M Jun/2025
Tectonic Therapeutic USD 1.74M 217K Dec/2024
Ultragenyx Pharmaceutical USD 5.79M 1.04M Jun/2025
Vertex Pharmaceuticals USD 122.4M 1.5M Jun/2025